Prague Med. Rep. 2026, 127, 21-26
https://doi.org/10.14712/23362936.2026.3
PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours
Ayushi Agarwal1, Charanjeet Ahluwalia1
, Kepeemadam Balasubramanyam Shankar2, Sana Ahuja1
, Kepeemadam Balasubramanyam Shankar2, Sana Ahuja1
1Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
2Department of Neurosurgery, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
Received June 24, 2025
Accepted February 26, 2026
References
1. , A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., Kurscheid, S., Hegi, M. E., Zielinski, C. C., Marosi, C., Hainfellner, J. A., Preusser, M., Wick, W. (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 17, 1064–1075.
<https://doi.org/10.1093/neuonc/nou307>
2. Brat, D., Ellison, D., Louis, D. (2021) WHO Classification of Tumours. Central Nervous System Tumors, 5th Edition. International Agency for Research on Cancer, Lyon.
3. , M., Scognamiglio, G., Collina, F., Liguori, G., Cantile, M., Botti, G. (2016) Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a “tumor score” definition. Int. J. Clin. Exp. Pathol. 9, 11693–11696.
4. , D. B., Chen, L. (2007) The new B7s: Playing a pivotal role in tumor immunity. J. Immunother. 30, 251–260.
<https://doi.org/10.1097/CJI.0b013e31802e085a>
5. , S., Massi, D., Mandalà, M. (2016) PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 100, 88–98.
<https://doi.org/10.1016/j.critrevonc.2016.02.001>
6. , D. H., Haaker, G., Delev, D., Mercas, B., Masalha, W., Heynckes, S., Gäbelein, A., Pfeifer, D., Carro, M. S., Weyerbrock, A., Prinz, M., Schnell, O. (2017) Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget 8, 42214–42225.
<https://doi.org/10.18632/oncotarget.15031>
7. , V., Raghuvanshi, S., Bhalla, S., Rawat, S., Ojha, B. K., Srivastava, C., Goel, M. M. (2025) Immunohistochemical expression of PDL1 and Ki67 in glioma and its correlation with treatment and overall survival. J. Cancer Res. Ther. 21, 145–150.
<https://doi.org/10.4103/jcrt.jcrt_2405_23>
8. , D., Perry, A., Wesseling, P., Brat, D., Cree, I., Figarella- Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., Ellison, D. W. (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 23, 1231–1251.
<https://doi.org/10.1093/neuonc/noab106>
9. , Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., Barnholtz-Sloan, J. S. (2019) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 21(Suppl. 5), v1–v100.
<https://doi.org/10.1093/neuonc/noz150>
10. , A., Wesseling, P. (2016) Histologic classification of gliomas. Handb. Clin. Neurol. 134, 71–95.
11. , N., Schiff, D. (2010) Management of low-grade glioma. Curr. Neurol. Neurosci. Rep. 10, 224–231.
<https://doi.org/10.1007/s11910-010-0105-7>
12. , M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., Stupp, R. (2011) Current concepts and management of glioblastoma. Ann. Neurol. 70, 9–21.
<https://doi.org/10.1002/ana.22425>
13. , Y., Weatherbee, J., Wheelhouse, R., Ross, A. (2013) Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 6, 1475–1506.
<https://doi.org/10.3390/ph6121475>
14. , D. (2011) Editorial: Low-grade gliomas. J. Neurosurg. 115, 945–947.
<https://doi.org/10.3171/2011.4.JNS11521>
15. , K., Molnar, P., Lapin, G., Groothuis, D. (1999) Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc. Res. 58, 312–328.
<https://doi.org/10.1006/mvre.1999.2188>
16. , S., Husain, N., Kaif, M., Awale, R., Mishra, S., Malhotra, K. (2021) Programmed death ligand-1 expression in gliomas: A study of histopathological and molecular associations. Neurol. India 69, 1005–1009.
<https://doi.org/10.4103/0028-3886.332255>
17. , H. L., Wadhwani, N., Horbinski, C. (2022) Major features of the 2021 WHO classification of CNS tumors. Neurotherapeutics 19, 1691–1704.
<https://doi.org/10.1007/s13311-022-01249-0>
18. , R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A., Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., Wesseling, P., Villa, S., Eisenhauer, E., Gorlia, T., Weller, M., Lacombe, D., Cairncross, J. G.,Mirimanoff, R. O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466.
<https://doi.org/10.1016/S1470-2045(09)70025-7>
19. , P. Y., DeAngelis, L. M. (2007) Chemotherapy for low-grade gliomas: Emerging consensus on its benefits. Neurology 68, 1762–1763.
<https://doi.org/10.1212/01.wnl.0000266866.13748.a9>
20. , J., Zhang, X. K., Chen, H. D., Zhong, Z. H., Wu, Q. L., Lin, S. X. (2016) Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 7, 8944–8955.
<https://doi.org/10.18632/oncotarget.6884>
21. , W., Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467–477.
<https://doi.org/10.1038/nri2326>
